CORTECH BRADYCOR SEPSIS TRIAL SHOWS NO SURVIVAL IMPROVEMENT
Executive Summary
CORTECH BRADYCOR SEPSIS TRIAL SHOWS NO SURVIVAL IMPROVEMENT in patients with systemic inflammatory response syndrome and presumed sepsis, the company reported July 21. Announcing results of its Phase II trial of the bradykinin antagonist, Cortech said "the primary analysis" of the trial results "did not demonstrate a clinically meaningful reduction in risk-adjusted 28-day survival." The 500-patient, 47-site study tested three dosing levels of three-day Bradycor infusion against placebo. "No safety concerns emerged" in the study, Cortech said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth